 | The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering
www.benzinga.com - August 14 at 4:02 PM |
 | CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants
finance.yahoo.com - August 14 at 4:02 PM |
| Oncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer
finance.yahoo.com - April 8 at 8:53 AM |
| Oncolytics Biotech(R) to Present at the 18th Annual Needham Healthcare Conference
finance.yahoo.com - April 3 at 8:51 AM |
| Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019
finance.yahoo.com - April 2 at 4:23 PM |
 | Oncolytics Biotech Inc. Estimate Momentum
www.nasdaq.com - March 18 at 4:06 PM |
 | Oncolytics Biotech Inc. (ONCY) CEO Matthew Coffey on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 8 at 12:25 PM |
| Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer
finance.yahoo.com - February 11 at 8:43 AM |
| Oncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor Conference
finance.yahoo.com - February 4 at 8:51 AM |
| Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and
www.nasdaq.com - December 12 at 11:05 AM |
| Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma
finance.yahoo.com - December 12 at 11:05 AM |
 | Oncolytics Biotech (ONCY) Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda
www.streetinsider.com - November 26 at 9:56 AM |
| Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer
finance.yahoo.com - November 26 at 9:56 AM |
| Oncolytics Biotech® Announces Attendance of Upcoming Conferences
finance.yahoo.com - November 13 at 9:13 AM |
| Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 12 at 3:23 PM |
| Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection
finance.yahoo.com - November 9 at 9:30 AM |
| Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate Highlights
finance.yahoo.com - November 5 at 8:46 AM |
| Oncolytics Biotech® Establishes New At-The-Market Facility
finance.yahoo.com - October 25 at 8:45 AM |
| Tiziana Life IPO: Phase 2 Of Development, But Expensive Shares
seekingalpha.com - October 23 at 3:22 PM |
| Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018
finance.yahoo.com - October 22 at 8:36 AM |
| Oncolytics Biotech (ONCY) Reports Publication of Positive Clinical Results for Pelareorep at ESMO 2018 Congress
www.streetinsider.com - October 11 at 8:21 AM |
| Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress
finance.yahoo.com - October 11 at 8:21 AM |
| Oncolytics (ONCY) Says Publication Shows Pelareorep Effectively Targets Tumors Even in Presence of Neutralizing Antibodies
www.streetinsider.com - October 3 at 8:18 AM |
| Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies
finance.yahoo.com - October 2 at 8:24 AM |
| Oncolytics Biotech (ONCY) Announces Common Stock Purchase Agreement for up to $26 Million with Lincoln Park Capital
www.streetinsider.com - September 28 at 3:21 PM |
| Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference
finance.yahoo.com - September 26 at 8:17 AM |
| Oncolytics Bio to update investors on business tomorrow morning
seekingalpha.com - September 20 at 7:46 AM |
| Oncolytics Biotech (ONCY) Provides Corporate, Clinical Update
www.streetinsider.com - September 20 at 7:46 AM |
| Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care
finance.yahoo.com - September 17 at 7:48 AM |
| Oncolytics Biotech collaborates with SOLTI to conduct a window of opportunity study in breast cancer with pelareorep
seekingalpha.com - September 10 at 3:19 PM |
| Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep
finance.yahoo.com - September 10 at 7:41 AM |
| Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program
finance.yahoo.com - September 6 at 7:43 AM |
| Oncolytics Biotech® Reports 2018 Second Quarter Results
finance.yahoo.com - August 3 at 3:17 PM |
| Oncolytics: Significant Pipeline Value In The Fastest Growing Area Of Oncology.
seekingalpha.com - July 11 at 3:16 PM |
 | Media Advisory - Oncolytics Biotech® Inc. Announces Participation In Upcoming Conferences
www.thestreet.com - February 9 at 12:04 PM |
| Oncolytics Biotech (ONCY) Commences Dosing in KEYTRUDA + REOLYSIN Phase 1b - StreetInsider.com
www.streetinsider.com - January 20 at 5:51 PM |
 | Oncolytics Biotech® Inc. Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer - PR Newswire (press release)
www.prnewswire.com - January 20 at 5:51 PM |
